{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"81.7","value":"185"},{"groupId":"OG001","spread":"197","value":"904"},{"groupId":"OG002","spread":"841","value":"2370"},{"groupId":"OG003","spread":"1820","value":"5400"},{"groupId":"OG004","spread":"5600","value":"10000"},{"groupId":"OG005","spread":"7720","value":"28300"},{"groupId":"OG006","spread":"9130","value":"61600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.21","value":"427"},{"groupId":"OG002","spread":"1560","value":"5490"},{"groupId":"OG003","spread":"6560","value":"10700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"To evaluate the AUC0-t of INCAGN01949 in subjects with advanced or metastatic solid tumors","dispersionType":"Standard Deviation","groups":[{"description":"INCAGN01949 7mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG000","title":"PART 1 Dose 1 (7 mg)"},{"description":"INCAGN01949 20mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG001","title":"PART 1 Dose 2 (20 mg)"},{"description":"INCAGN01949 70mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG002","title":"PART 1 Dose 3 (70 mg)"},{"description":"INCAGN01949 200mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG003","title":"PART 1 Dose 4 (200 mg)"},{"description":"INCAGN01949 350mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG004","title":"PART 1 Dose 5 (350 mg)"},{"description":"INCAGN01949 700mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG005","title":"PART 1 Dose 6 (700 mg)"},{"description":"INCAGN01949 1400mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG006","title":"PART 1 Dose 7 (1400 mg)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK evaluable population will include all subjects who received at least 1 dose of INCAGN01949 and provided at least 1 post dose sample (1 PK measurement).","reportingStatus":"POSTED","timeFrame":"Pre-infusion for cycles 1,2,3,4,5,6 and 7, 10-minutes, 4 hrs, 24 hrs post-infusion, Day 8 for cycles 1 & 6","title":"Area Under the Single-dose Concentration-time Curve (AUC0-t) of INCAGN01949","type":"SECONDARY","unitOfMeasure":"ug*hr/mL"}